In summary, our in vitro data show that EGFR-related TKIs and cetuximab are able to enhance antitumoral activity of NK cells in ovarian cancer cells, even if the tumor cells themselves are functionally resistant to the anti-EGFR agents. This evidence concerns the gene EGFR and ovarian cancer.